Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the treatment of chronic kidney disease, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism, Cushing syndrome, kidney and myocardial fibrosis.